Jianrong Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jianrong Li has a total of 667 co-authors. Here are the top co-authors by number of shared publications:
Xueya Liang
Department of Veterinary Biosciences, The Ohio State University
21 shared publicationsYuanmei Ma
Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH 43210
19 shared publicationsMijia Lu
Department of Veterinary Biosciences, The Ohio State University, Columbus, USA
16 shared publications- Mark Edward Peeples
Center for Microbe and Immunity Research, Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, OH, USA
15 shared publications Yuexiu Zhang
Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, Ohio, USA
15 shared publications- Erin DiCaprio
Department of Food Science and Technology, University of California, Davis
12 shared publications
Latest Publications
- Open Access
Gene duplication and retrotransposition diversify the antiviral repertoire of macaque IFITM proteins
Interferon-induced transmembrane (IFITM) proteins are broad-spectrum antiviral restriction factors that inhibit viral entry of diverse enveloped viruses. Comparative genomic studies have revealed extensive lineage-specific diversification of IFITM genes, yet the functional consequences of this diversification remain poorly understood. We previously identified an expanded IFITM repertoire in macaques consisting of the canonical IFITM proteins, IFITM1 and IFITM3, a duplicated IFITM3 paralog (IFITM3A), and two retrotransposed IFITM3-derived genes (IFITM3-R1 and IFITM3-R2). Here, we thoroughly characterized the antiviral activities, intracellular localization, and mechanisms of regulation of canonical and non-canonical macaque IFITMs against vesicular stomatitis virus (VSV), influenza A virus (IAV), Sendai virus, and HIV-1. IFITM3A exhibited enhanced antiviral activity relative to IFITM3, particularly against VSV and HIV-1. Comparative mutational analyses identified amino acid substitutions in IFITM3 that contribute to the enhanced antiviral phenotype of IFITM3A. In contrast, the retrocopy IFITM3-R1 exhibited markedly reduced expression due to lysosome-dependent protein turnover mediated by a PPxY motif and a unique lysine residue (K51). Alteration of these determinants increased IFITM3-R1 expression and selectively enhanced restriction of VSV and IAV. Although several macaque IFITMs reduced HIV-1 infectivity when expressed in producer cells, none significantly inhibited HIV-1 infection in target cells. Furthermore, differential incorporation of IFITMs into HIV-1 virions did not consistently correlate with antiviral activity, indicating that virion incorporation alone is insufficient to explain HIV-1 restriction. Together, these findings demonstrate that gene duplication and retrotransposition have generated a functionally diverse IFITM repertoire in macaques and provide insight into how evolutionary diversification expands innate antiviral defenses in primates. Importance: IFITM proteins are broad-spectrum antiviral restriction factors that inhibit infection of numerous enveloped viruses. Although IFITM genes have undergone extensive diversification during mammalian evolution, the functional consequences of this diversification remain poorly understood. Here, we show that expansion of the macaque IFITM locus through gene duplication and retrotransposition generated proteins with distinct antiviral activities, intracellular localization patterns, and regulatory mechanisms. We identify amino acid determinants that contribute to the enhanced antiviral activity of the duplicated paralog IFITM3A and demonstrate that lysosome-dependent turnover mediated by a PPxY motif and a unique lysine residue limits expression and antiviral activity of the retrocopy IFITM3-R1. We further show that macaque IFITMs inhibit HIV-1 predominantly through producer-cell-dependent mechanisms and reveal that IFITM virion incorporation alone does not predict antiviral potency. These findings provide mechanistic insight into how restriction factor diversification expands innate antiviral defenses and shapes host-virus interactions in primates.
Open AccessGene duplication and retrotransposition diversify the antiviral repertoire of macaque IFITM proteins
Interferon-induced transmembrane (IFITM) proteins are broad-spectrum antiviral restriction factors that inhibit viral entry of diverse enveloped viruses. Comparative genomic studies have revealed extensive lineage-specific diversification of IFITM genes, yet the functional consequences of this diversification remain poorly understood. We previously identified an expanded IFITM repertoire in macaques consisting of the canonical IFITM proteins, IFITM1 and IFITM3, a duplicated IFITM3 paralog (IFITM3A), and two retrotransposed IFITM3-derived genes (IFITM3-R1 and IFITM3-R2). Here, we thoroughly characterized the antiviral activities, intracellular localization, and mechanisms of regulation of canonical and non-canonical macaque IFITMs against vesicular stomatitis virus (VSV), influenza A virus (IAV), Sendai virus, and HIV-1. IFITM3A exhibited enhanced antiviral activity relative to IFITM3, particularly against VSV and HIV-1. Comparative mutational analyses identified amino acid substitutions in IFITM3 that contribute to the enhanced antiviral phenotype of IFITM3A. In contrast, the retrocopy IFITM3-R1 exhibited markedly reduced expression due to lysosome-dependent protein turnover mediated by a PPxY motif and a unique lysine residue (K51). Alteration of these determinants increased IFITM3-R1 expression and selectively enhanced restriction of VSV and IAV. Although several macaque IFITMs reduced HIV-1 infectivity when expressed in producer cells, none significantly inhibited HIV-1 infection in target cells. Furthermore, differential incorporation of IFITMs into HIV-1 virions did not consistently correlate with antiviral activity, indicating that virion incorporation alone is insufficient to explain HIV-1 restriction. Together, these findings demonstrate that gene duplication and retrotransposition have generated a functionally diverse IFITM repertoire in macaques and provide insight into how evolutionary diversification expands innate antiviral defenses in primates. Importance: IFITM proteins are broad-spectrum antiviral restriction factors that inhibit infection of numerous enveloped viruses. Although IFITM genes have undergone extensive diversification during mammalian evolution, the functional consequences of this diversification remain poorly understood. Here, we show that expansion of the macaque IFITM locus through gene duplication and retrotransposition generated proteins with distinct antiviral activities, intracellular localization patterns, and regulatory mechanisms. We identify amino acid determinants that contribute to the enhanced antiviral activity of the duplicated paralog IFITM3A and demonstrate that lysosome-dependent turnover mediated by a PPxY motif and a unique lysine residue limits expression and antiviral activity of the retrocopy IFITM3-R1. We further show that macaque IFITMs inhibit HIV-1 predominantly through producer-cell-dependent mechanisms and reveal that IFITM virion incorporation alone does not predict antiviral potency. These findings provide mechanistic insight into how restriction factor diversification expands innate antiviral defenses and shapes host-virus interactions in primates.
- Open Access
- 10 June 2026
- Published by American Society for Microbiology in mBio
- Vol. 17 (6) , e0012226
A rapid yeast-based reverse genetics system reveals SARS-CoV-2 Omicron BA.2.86 variant spreads faster than Omicron JN.1 variant in primary human nasal and bronchial epithelial airway cultures
Since the COVID-19 pandemic, several reverse genetics platforms for SARS-CoV-2 have been established. In general, a plasmid-based reverse genetics system is stable and easy to manipulate, distribute, and store. However, traditional methods for the assembly of a large viral genome in a plasmid rely on natural and artificially engineered restriction sites, which are inefficient, time-consuming, labor-intensive, and frequently not successful. Here, we developed a yeast-based homologous recombination system that allows the assembly of the SARS-CoV-2 genome as a cDNA in a bacterial artificial chromosome (BAC) plasmid in a single step. The entire protocol from cDNA construction to virus rescue is simple, rapid, accurate, highly efficient, and can be completed in 2 weeks. Using this system, we have quickly generated recombinant SARS-CoV-2 (rSARS-CoV-2) WA1, Omicron BA.2.86, and Omicron JN.1 viruses expressing mCherry, green fluorescent protein (GFP), and NanoLuc luciferase (Nluc) reporters. Insertion of these reporter genes does not significantly alter the replication of SARS-CoV-2 in cell culture. We also compared the replication kinetics of rSARS-CoV-2-WA1, BA.2.86, and JN.1 reporter viruses in ex vivo primary human nasal epithelial (HNE) and human bronchial epithelial (HBE) cultures. Omicron BA.2.86 replicated and spread more efficiently than JN.1, which spread much faster than SARS-CoV-2 WA1 in these cultures. In summary, we have developed a highly efficient yeast-based recombinant system for the construction of infectious cDNA clones of SARS-CoV-2, enabling rapid genetic manipulation of SARS-CoV-2. In addition, the reporter viruses generated in this study will be useful for monitoring SARS-CoV-2 infection in vitro and in vivo . IMPORTANCE: Reverse genetics systems are an essential tool for probing the biology of viruses, testing antivirals, and developing live-attenuated vaccines. However, it has been a challenge to generate a rapid reverse genetics system for coronaviruses. Here, we developed a rapid, highly efficient reverse genetics system for SARS-CoV-2 that uses yeast homologous recombination. In this procedure, overlapping DNA fragments encompassing the entire SARS-CoV-2 and BAC plasmid fragments containing a yeast replication origin were mixed and transformed into yeast cells to assemble infectious cDNA clones in a single step. This system has enabled us to rapidly generate nine SARS-CoV-2 viruses: WA1, Omicron BA.2.86, and JN.1 viruses each expressing one of three reporters for tracking virus infection in vitro and in vivo . This method is easy, convenient, and highly efficient, generating infectious cDNA clones within 2 weeks. This system could readily be adapted to construct infectious cDNA clones for other large RNA viruses.
- 10 June 2026
- Published by American Society for Microbiology in mBio
- Vol. 17 (6) , e0012226
Open AccessA rapid yeast-based reverse genetics system reveals SARS-CoV-2 Omicron BA.2.86 variant spreads faster than Omicron JN.1 variant in primary human nasal and bronchial epithelial airway cultures
Since the COVID-19 pandemic, several reverse genetics platforms for SARS-CoV-2 have been established. In general, a plasmid-based reverse genetics system is stable and easy to manipulate, distribute, and store. However, traditional methods for the assembly of a large viral genome in a plasmid rely on natural and artificially engineered restriction sites, which are inefficient, time-consuming, labor-intensive, and frequently not successful. Here, we developed a yeast-based homologous recombination system that allows the assembly of the SARS-CoV-2 genome as a cDNA in a bacterial artificial chromosome (BAC) plasmid in a single step. The entire protocol from cDNA construction to virus rescue is simple, rapid, accurate, highly efficient, and can be completed in 2 weeks. Using this system, we have quickly generated recombinant SARS-CoV-2 (rSARS-CoV-2) WA1, Omicron BA.2.86, and Omicron JN.1 viruses expressing mCherry, green fluorescent protein (GFP), and NanoLuc luciferase (Nluc) reporters. Insertion of these reporter genes does not significantly alter the replication of SARS-CoV-2 in cell culture. We also compared the replication kinetics of rSARS-CoV-2-WA1, BA.2.86, and JN.1 reporter viruses in ex vivo primary human nasal epithelial (HNE) and human bronchial epithelial (HBE) cultures. Omicron BA.2.86 replicated and spread more efficiently than JN.1, which spread much faster than SARS-CoV-2 WA1 in these cultures. In summary, we have developed a highly efficient yeast-based recombinant system for the construction of infectious cDNA clones of SARS-CoV-2, enabling rapid genetic manipulation of SARS-CoV-2. In addition, the reporter viruses generated in this study will be useful for monitoring SARS-CoV-2 infection in vitro and in vivo . IMPORTANCE: Reverse genetics systems are an essential tool for probing the biology of viruses, testing antivirals, and developing live-attenuated vaccines. However, it has been a challenge to generate a rapid reverse genetics system for coronaviruses. Here, we developed a rapid, highly efficient reverse genetics system for SARS-CoV-2 that uses yeast homologous recombination. In this procedure, overlapping DNA fragments encompassing the entire SARS-CoV-2 and BAC plasmid fragments containing a yeast replication origin were mixed and transformed into yeast cells to assemble infectious cDNA clones in a single step. This system has enabled us to rapidly generate nine SARS-CoV-2 viruses: WA1, Omicron BA.2.86, and JN.1 viruses each expressing one of three reporters for tracking virus infection in vitro and in vivo . This method is easy, convenient, and highly efficient, generating infectious cDNA clones within 2 weeks. This system could readily be adapted to construct infectious cDNA clones for other large RNA viruses.
- Open Access
- 26 September 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (39) , eadx7487
Development of SARS-CoV-2 as a viral vector: A novel intranasal bivalent vaccine for SARS-CoV-2 and RSV
Negative-sense RNA viruses have been widely used as viral vectors for vaccine delivery. However, little is known about coronaviruses as vectors for delivering vaccines. Here, we have developed safe SARS-CoV-2 Omicron JN.1–based live attenuated vaccine candidates by combining a mutation (D130A) in the viral nsp16 protein, deletion of the furin cleavage site (dFCS) in the spike protein, deletion of accessory proteins, and/or modification of the transcription regulatory sequences (mTRS). Subsequently, using rJN.1, rJN.1-D130A-dFCS, and rJN.1-mTRS-D130A-dFCS as the backbones, we generated three recombinant viruses expressing a nonfunctional, soluble, and stabilized prefusion F protein of human respiratory syncytial virus (RSVF). Among them, rJN.1-D130A-dFCS-RSVF virus was sufficiently attenuated and highly immunogenic, providing complete protection against challenge with both JN.1 and RSV in hamsters. However, rJN.1-mTRS-D130A-dFCS-RSVF was poorly immunogenic. Collectively, we demonstrate that attenuated SARS-CoV-2 is an effective viral vector for delivering RSV vaccine, warranting further development as a novel intranasal bivalent vaccine for SARS-CoV-2 and RSV.
- 26 September 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (39) , eadx7487
Open AccessDevelopment of SARS-CoV-2 as a viral vector: A novel intranasal bivalent vaccine for SARS-CoV-2 and RSV
Negative-sense RNA viruses have been widely used as viral vectors for vaccine delivery. However, little is known about coronaviruses as vectors for delivering vaccines. Here, we have developed safe SARS-CoV-2 Omicron JN.1–based live attenuated vaccine candidates by combining a mutation (D130A) in the viral nsp16 protein, deletion of the furin cleavage site (dFCS) in the spike protein, deletion of accessory proteins, and/or modification of the transcription regulatory sequences (mTRS). Subsequently, using rJN.1, rJN.1-D130A-dFCS, and rJN.1-mTRS-D130A-dFCS as the backbones, we generated three recombinant viruses expressing a nonfunctional, soluble, and stabilized prefusion F protein of human respiratory syncytial virus (RSVF). Among them, rJN.1-D130A-dFCS-RSVF virus was sufficiently attenuated and highly immunogenic, providing complete protection against challenge with both JN.1 and RSV in hamsters. However, rJN.1-mTRS-D130A-dFCS-RSVF was poorly immunogenic. Collectively, we demonstrate that attenuated SARS-CoV-2 is an effective viral vector for delivering RSV vaccine, warranting further development as a novel intranasal bivalent vaccine for SARS-CoV-2 and RSV.
- Open Access
- 30 August 2025
- Published by Springer Nature
- Vol. 48 (2) , 59-71
A Rapid Yeast-Based System for Modifying Respiratory Syncytial Virus
Background. Respiratory syncytial virus (RSV) is the leading cause of infant hospitalisation. In 2022, nirsevimab was approved in the European Union to prevent severe respiratory disease due to RSV during the first year of life. Our aim is to evaluate the effectiveness of nirsevimab immunoprophylaxis in new-borns for preventing RSV -related hospitalisations in Navarre, Spain, during its first two seasons of use. Methods. Nirsevimab was offered free of charge to infants born from October to December 2023 and from September to December 2024. Each cohort was followed until February of the following year. Cases were infants hospitalised for PCR-confirmed RSV infection. Cox regression was used to estimate the hazard ratio of hospitalisation for immunised versus non-immunised children. Results. Nirsevimab was offered to 2,699 new-borns; of them, 2,541 (94.1%) received nirsevimab. In the 2023-2024 season, 17 RSV-related hospitalisations were recorded and 24 in the 2024-2025 season. The average risk of RSV hospitalisation was 7.6% in non-immunised new-borns versus 1.1% in immunised ones. Overall, effectiveness of nirsevimab was 79.5% (95% CI: 59.2 - 89.7), with estimates of 89.9% in 2023-2024 and 52.8% in 2024-2025, with no significant differences between seasons (p=0.055). On average, one RSV hospitalisation was prevented per 22.6 immunised infants. Conclusions. Nirsevimab immunoprophylaxis substantially reduces RSV hospitalisations, helping ease paediatric hospital burden. However, as some immunised infants were still hospitalised, additional preventive measures remain necessary. Fundamento. La infección por el virus respiratorio sincitial (VRS) es la principal causa de hospitalización en lactantes. En 2022 se autorizó el nirsevimab en la Unión Europea para prevenir la enfermedad respiratoria grave por VRS durante el primer año de vida. Evaluamos la efectividad de la inmunoprofilaxis con nirsevimab en recién nacidos para prevenir hospitalizaciones por VRS en Navarra durante las dos primeras temporadas de implementación. Métodos. Se ofreció nirsevimab a las cohortes de recién nacidos de octubre a diciembre de 2023 y de septiembre a diciembre de 2024, que se siguieron hasta febrero del año siguiente. Se consideraron casos a las hospitalizaciones por VRS confirmadas por PCR. Mediante regresión de Cox se estimó la razón de riesgos de hospitalización por VRS de inmunizados frente a no inmunizados. Resultados. Se ofreció nirsevimab a 2.699 recién nacidos, y 2.541 lo recibieron (94,1%). Se registraron 17 hospitalizaciones por VRS en la temporada 2023-2024 y 24 en la 2024-2025. El riesgo promedio de hospitalización por VRS fue 7,6% en no inmunizados y 1,1% en inmunizados. La efectividad promedio del nirsevimab para prevenir hospitalizaciones por VRS fue 79,5% (IC95%: 59,2-89,7), 89,9% en la temporada 2023-2024 y 52,8% en la 2024-2025, sin diferencias significativas entre ambas (p=0,055). La inmunoprofilaxis previno en promedio una hospitalización por VRS por cada 22,6 inmunizados. Conclusiones. La inmunoprofilaxis con nirsevimab resultó efectiva para prevenir hospitalizaciones por VRS y alivió la sobrecarga de ingresos pediátricos. Ante la posibilidad de casos en inmunizados, debe complementarse con otras medidas preventivas.
- 30 August 2025
- Published by Springer Nature
- Vol. 48 (2) , 59-71
Open AccessA Rapid Yeast-Based System for Modifying Respiratory Syncytial Virus
Background. Respiratory syncytial virus (RSV) is the leading cause of infant hospitalisation. In 2022, nirsevimab was approved in the European Union to prevent severe respiratory disease due to RSV during the first year of life. Our aim is to evaluate the effectiveness of nirsevimab immunoprophylaxis in new-borns for preventing RSV -related hospitalisations in Navarre, Spain, during its first two seasons of use. Methods. Nirsevimab was offered free of charge to infants born from October to December 2023 and from September to December 2024. Each cohort was followed until February of the following year. Cases were infants hospitalised for PCR-confirmed RSV infection. Cox regression was used to estimate the hazard ratio of hospitalisation for immunised versus non-immunised children. Results. Nirsevimab was offered to 2,699 new-borns; of them, 2,541 (94.1%) received nirsevimab. In the 2023-2024 season, 17 RSV-related hospitalisations were recorded and 24 in the 2024-2025 season. The average risk of RSV hospitalisation was 7.6% in non-immunised new-borns versus 1.1% in immunised ones. Overall, effectiveness of nirsevimab was 79.5% (95% CI: 59.2 - 89.7), with estimates of 89.9% in 2023-2024 and 52.8% in 2024-2025, with no significant differences between seasons (p=0.055). On average, one RSV hospitalisation was prevented per 22.6 immunised infants. Conclusions. Nirsevimab immunoprophylaxis substantially reduces RSV hospitalisations, helping ease paediatric hospital burden. However, as some immunised infants were still hospitalised, additional preventive measures remain necessary. Fundamento. La infección por el virus respiratorio sincitial (VRS) es la principal causa de hospitalización en lactantes. En 2022 se autorizó el nirsevimab en la Unión Europea para prevenir la enfermedad respiratoria grave por VRS durante el primer año de vida. Evaluamos la efectividad de la inmunoprofilaxis con nirsevimab en recién nacidos para prevenir hospitalizaciones por VRS en Navarra durante las dos primeras temporadas de implementación. Métodos. Se ofreció nirsevimab a las cohortes de recién nacidos de octubre a diciembre de 2023 y de septiembre a diciembre de 2024, que se siguieron hasta febrero del año siguiente. Se consideraron casos a las hospitalizaciones por VRS confirmadas por PCR. Mediante regresión de Cox se estimó la razón de riesgos de hospitalización por VRS de inmunizados frente a no inmunizados. Resultados. Se ofreció nirsevimab a 2.699 recién nacidos, y 2.541 lo recibieron (94,1%). Se registraron 17 hospitalizaciones por VRS en la temporada 2023-2024 y 24 en la 2024-2025. El riesgo promedio de hospitalización por VRS fue 7,6% en no inmunizados y 1,1% en inmunizados. La efectividad promedio del nirsevimab para prevenir hospitalizaciones por VRS fue 79,5% (IC95%: 59,2-89,7), 89,9% en la temporada 2023-2024 y 52,8% en la 2024-2025, sin diferencias significativas entre ambas (p=0,055). La inmunoprofilaxis previno en promedio una hospitalización por VRS por cada 22,6 inmunizados. Conclusiones. La inmunoprofilaxis con nirsevimab resultó efectiva para prevenir hospitalizaciones por VRS y alivió la sobrecarga de ingresos pediátricos. Ante la posibilidad de casos en inmunizados, debe complementarse con otras medidas preventivas.
- 30 August 2025
- Published by Springer Nature
- Vol. 2948, 249-265
Well-Differentiated Primary Human Airway Epithelial Cultures for Respiratory Syncytial Virus (RSV) Infection Studies
The addition of marker protein genes to respiratory syncytial virus (RSV) has enabled studies of the spread of RSV in different types of cell cultures and quantification of viral replication in those cultures. Genetic deletion of individual RSV genes from RSV genome has been used to determine their importance in virus infection and the differences between infection of cultured cells lines and of primary well-differentiated human bronchial epithelial (HBE) cultures. Modifications of individual viral proteins can identify the importance of a particular glycosylation, cleavage, or antigenic sites or reveal sites with these functions. However, the standard recombinant systems for the RSV genome, based on natural and inserted restriction sites, have been difficult to use, slow to accomplish, and frequently not successful. Here, we describe a yeast-based cDNA assembly system that streamlines both the construction of a cDNA clone of an RSV strain as well as any modification of an RSV cDNA, thereby enabling the rapid generation of an RSV mutant virus.
- 30 August 2025
- Published by Springer Nature
- Vol. 2948, 249-265
Well-Differentiated Primary Human Airway Epithelial Cultures for Respiratory Syncytial Virus (RSV) Infection Studies
The addition of marker protein genes to respiratory syncytial virus (RSV) has enabled studies of the spread of RSV in different types of cell cultures and quantification of viral replication in those cultures. Genetic deletion of individual RSV genes from RSV genome has been used to determine their importance in virus infection and the differences between infection of cultured cells lines and of primary well-differentiated human bronchial epithelial (HBE) cultures. Modifications of individual viral proteins can identify the importance of a particular glycosylation, cleavage, or antigenic sites or reveal sites with these functions. However, the standard recombinant systems for the RSV genome, based on natural and inserted restriction sites, have been difficult to use, slow to accomplish, and frequently not successful. Here, we describe a yeast-based cDNA assembly system that streamlines both the construction of a cDNA clone of an RSV strain as well as any modification of an RSV cDNA, thereby enabling the rapid generation of an RSV mutant virus.
- 30 August 2025
- Published by Springer Nature
- Vol. 2948, 233-247
Bisulfite Sequencing to Map 5-Methylcytosine Sites in Human Respiratory Syncytial Virus RNA
Viral epigenetic modification is an emerging field. As an obligate intracellular parasite, viral genetic material is exposed to host RNA-modifying enzymes. Currently, more than 180 types of RNA modifications have been identified. Like all non-segmented negative-sense RNA viruses, human respiratory syncytial virus (RSV) infection produces three types of RNA: genome and antigenome that are encapsidated by viral nucleocapsid and 10 mRNAs that are capped, methylated, and polyadenylated. Recently, the RSV genome, antigenome, and mRNAs have been shown to be modified by N6-methyladenosine (m6A), which plays critical roles in replication, gene expression, and innate immune responses. However, whether RSV RNAs contain other types of modification remains unclear. Here, we describe an optimized bisulfite sequencing method and rigorous data analysis procedure to quantitatively map 5-methylcytosine (m5C), one of the most prevalent RNA modifications, in RNA isolated from A549 cells infected by RSV and vesicular stomatitis virus (VSV) at single-base resolution. This method identified 20 m5C sites in RSV genome but no m5C sites were found in RSV antigenome, RSV mRNAs, or VSV RNAs. This protocol can be easily adapted for m5C mapping of the RNAs of other viruses.
- 30 August 2025
- Published by Springer Nature
- Vol. 2948, 233-247
Bisulfite Sequencing to Map 5-Methylcytosine Sites in Human Respiratory Syncytial Virus RNA
Viral epigenetic modification is an emerging field. As an obligate intracellular parasite, viral genetic material is exposed to host RNA-modifying enzymes. Currently, more than 180 types of RNA modifications have been identified. Like all non-segmented negative-sense RNA viruses, human respiratory syncytial virus (RSV) infection produces three types of RNA: genome and antigenome that are encapsidated by viral nucleocapsid and 10 mRNAs that are capped, methylated, and polyadenylated. Recently, the RSV genome, antigenome, and mRNAs have been shown to be modified by N6-methyladenosine (m6A), which plays critical roles in replication, gene expression, and innate immune responses. However, whether RSV RNAs contain other types of modification remains unclear. Here, we describe an optimized bisulfite sequencing method and rigorous data analysis procedure to quantitatively map 5-methylcytosine (m5C), one of the most prevalent RNA modifications, in RNA isolated from A549 cells infected by RSV and vesicular stomatitis virus (VSV) at single-base resolution. This method identified 20 m5C sites in RSV genome but no m5C sites were found in RSV antigenome, RSV mRNAs, or VSV RNAs. This protocol can be easily adapted for m5C mapping of the RNAs of other viruses.
- Open Access
- 19 August 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-19
O-GlcNAc transferase plays dual antiviral roles by integrating innate immunity and lipid metabolism
Viral infection induces robust reprogramming of metabolic pathways in host cells. However, whether host metabolic enzymes detect viral components remains unknown. Our group and others previously identified O-GlcNAc transferase (OGT), an important glucose metabolic enzyme, as a crucial mediator of the antiviral immune responses. Here, by studying a mouse model with a catalytically impaired OGT, we discover a catalytic activity-independent function of OGT in restraining influenza A virus (IAV) infection in addition to its catalytic activity-dependent effect on MAVS-mediated antiviral immunity. Biochemical studies reveal a critical antiviral effect based on OGT interacting with IAV genomic RNA that requires its N-terminal tetracopeptide repeat-4 motif. This interaction causes the translocation of nuclear OGT to cytosolic lipid droplets (LDs) to destabilize LDs-coating perilipin 2, thereby limiting LDs accumulation and in turn virus replication. In sum, our findings reveal OGT as a multifaceted metabolic sensor that integrates MAVS signaling and lipid metabolism to combat viral infection.
- 19 August 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-19
Open AccessO-GlcNAc transferase plays dual antiviral roles by integrating innate immunity and lipid metabolism
Viral infection induces robust reprogramming of metabolic pathways in host cells. However, whether host metabolic enzymes detect viral components remains unknown. Our group and others previously identified O-GlcNAc transferase (OGT), an important glucose metabolic enzyme, as a crucial mediator of the antiviral immune responses. Here, by studying a mouse model with a catalytically impaired OGT, we discover a catalytic activity-independent function of OGT in restraining influenza A virus (IAV) infection in addition to its catalytic activity-dependent effect on MAVS-mediated antiviral immunity. Biochemical studies reveal a critical antiviral effect based on OGT interacting with IAV genomic RNA that requires its N-terminal tetracopeptide repeat-4 motif. This interaction causes the translocation of nuclear OGT to cytosolic lipid droplets (LDs) to destabilize LDs-coating perilipin 2, thereby limiting LDs accumulation and in turn virus replication. In sum, our findings reveal OGT as a multifaceted metabolic sensor that integrates MAVS signaling and lipid metabolism to combat viral infection.
- Open Access
- 6 August 2025
- Vol. 122 (32)
Intranasal measles virus- and mumps virus-based SARS-CoV-2 vaccine candidates prevent SARS-CoV-2 infection and transmission.
The emergence of immune-evasive SARS-CoV-2 Omicron subvariants highlights the need to develop a mucosal SARS-CoV-2 vaccine that can provide broad protection against virus infection and transmission. Here, we developed an intranasal monovalent SARS-CoV-2 vaccine expressing the six-proline-stabilized prefusion spike proteins (preS-6P) of Omicron XBB.1.5 based on the attenuated mumps virus (MuV) Jeryl Lynn (JL1) vaccine strain. We also developed an intranasal trivalent vaccine expressing the preS-6P of ancestral SARS-CoV-2 WA1 and two Omicron subvariants, BA.1 and XBB.1.5, using the attenuated measles virus (MeV) and MuV-JL1 and JL2 vaccine strains, respectively. Intranasal immunization of hamsters with the monovalent rMuV-JL1-XBB.1.5 or the trivalent vaccine induced high levels of neutralizing antibodies (NAbs) that efficiently neutralized Omicron subvariants XBB.1.5, EG.5, and JN.1, providing complete protection against these Omicron subvariants. Similar levels of Omicron XBB.1.5 NAbs were detected in monovalent rMuV-JL1-XBB.1.5 and trivalent vaccine groups even when hamsters had been preimmunized with the rMuV-JL2-WA1 vaccine, suggesting that both intranasal vaccines are effective in the presence of immune imprinting induced by the spike of SARS-CoV-2 WA1. Intranasal, but not subcutaneous, immunization generated high levels of S-specific mucosal IgA antibodies as well as lung-resident memory T cells in IFNAR1-/- mice. Finally, intranasal immunization with the trivalent vaccine efficiently blocked transmission of SARS-CoV-2 WA1 and Omicron XBB.1.5 among hamsters in a direct contact transmission setting. In summary, we have developed intranasal MeV and MuV-based trivalent vaccines that induce broad NAbs, robust mucosal immunity, and strong protection against both virus challenge and virus transmission.
- 6 August 2025
- Vol. 122 (32)
Open AccessIntranasal measles virus- and mumps virus-based SARS-CoV-2 vaccine candidates prevent SARS-CoV-2 infection and transmission.
The emergence of immune-evasive SARS-CoV-2 Omicron subvariants highlights the need to develop a mucosal SARS-CoV-2 vaccine that can provide broad protection against virus infection and transmission. Here, we developed an intranasal monovalent SARS-CoV-2 vaccine expressing the six-proline-stabilized prefusion spike proteins (preS-6P) of Omicron XBB.1.5 based on the attenuated mumps virus (MuV) Jeryl Lynn (JL1) vaccine strain. We also developed an intranasal trivalent vaccine expressing the preS-6P of ancestral SARS-CoV-2 WA1 and two Omicron subvariants, BA.1 and XBB.1.5, using the attenuated measles virus (MeV) and MuV-JL1 and JL2 vaccine strains, respectively. Intranasal immunization of hamsters with the monovalent rMuV-JL1-XBB.1.5 or the trivalent vaccine induced high levels of neutralizing antibodies (NAbs) that efficiently neutralized Omicron subvariants XBB.1.5, EG.5, and JN.1, providing complete protection against these Omicron subvariants. Similar levels of Omicron XBB.1.5 NAbs were detected in monovalent rMuV-JL1-XBB.1.5 and trivalent vaccine groups even when hamsters had been preimmunized with the rMuV-JL2-WA1 vaccine, suggesting that both intranasal vaccines are effective in the presence of immune imprinting induced by the spike of SARS-CoV-2 WA1. Intranasal, but not subcutaneous, immunization generated high levels of S-specific mucosal IgA antibodies as well as lung-resident memory T cells in IFNAR1-/- mice. Finally, intranasal immunization with the trivalent vaccine efficiently blocked transmission of SARS-CoV-2 WA1 and Omicron XBB.1.5 among hamsters in a direct contact transmission setting. In summary, we have developed intranasal MeV and MuV-based trivalent vaccines that induce broad NAbs, robust mucosal immunity, and strong protection against both virus challenge and virus transmission.
- Open Access
AI-based decoding of long covid cognitive impairments in mice using automated behavioral system and comparative transcriptomic analysis
Long COVID (LC) following SARS-CoV-2 infection affects millions of individuals world-wide and manifests with a variety of symptoms including cognitive dysfunction also known as “brain fog”. This is characterized by difficulties in executive functions, planning, decision-making, working memory, impairments in complex attention, loss of ability to learn new skills and perform sophisticated brain tasks. No effective treatment options currently exist for LC-related cognitive dysfunction. Here, we use the IntelliCage, which is an automated tracking system of cognitive functions, following SARS-CoV-2 infection in mice, measuring the ability of each mouse within a group to perform tasks that mimic complex human behaviors, such as planning, decision-making, cognitive flexibility, and working memory. Artificial intelligence and machine learning analyses of the tracking data classified LC mice into distinct behavioral categories from non-infected control mice, permitting precise identification and quantification of complex cognitive dysfunction in a controlled, replicable manner. Importantly, we find that brains from LC mice with cognitive dysfunction exhibit transcriptomic alterations similar to those observed in humans suffering from LC-related cognitive impairments, including altered expression of genes involved in learning, executive functions, synaptic functions, neurotransmitters and memory. Together, our findings establish a validated murine model and an automated unbiased approach to study LC-related cognitive dysfunction for the first time, and providing a valuable tool for screening potential treatments and therapeutic interventions.
Open AccessAI-based decoding of long covid cognitive impairments in mice using automated behavioral system and comparative transcriptomic analysis
Long COVID (LC) following SARS-CoV-2 infection affects millions of individuals world-wide and manifests with a variety of symptoms including cognitive dysfunction also known as “brain fog”. This is characterized by difficulties in executive functions, planning, decision-making, working memory, impairments in complex attention, loss of ability to learn new skills and perform sophisticated brain tasks. No effective treatment options currently exist for LC-related cognitive dysfunction. Here, we use the IntelliCage, which is an automated tracking system of cognitive functions, following SARS-CoV-2 infection in mice, measuring the ability of each mouse within a group to perform tasks that mimic complex human behaviors, such as planning, decision-making, cognitive flexibility, and working memory. Artificial intelligence and machine learning analyses of the tracking data classified LC mice into distinct behavioral categories from non-infected control mice, permitting precise identification and quantification of complex cognitive dysfunction in a controlled, replicable manner. Importantly, we find that brains from LC mice with cognitive dysfunction exhibit transcriptomic alterations similar to those observed in humans suffering from LC-related cognitive impairments, including altered expression of genes involved in learning, executive functions, synaptic functions, neurotransmitters and memory. Together, our findings establish a validated murine model and an automated unbiased approach to study LC-related cognitive dysfunction for the first time, and providing a valuable tool for screening potential treatments and therapeutic interventions.
- Top Cited PapersOpen Access
- 14 May 2025
- Published by American Society for Microbiology in mBio
- Vol. 16 (5) , e0046425
Neutralization and spike stability of JN.1-derived LB.1, KP.2.3, KP.3, and KP.3.1.1 subvariants
During the summer of 2024, coronavirus disease 2019 (COVID-19) cases surged globally, driven by variants derived from JN.1 subvariants of severe acute respiratory syndrome coronavirus 2 that feature new mutations, particularly in the N-terminal domain (NTD) of the spike protein. In this study, we report on the neutralizing antibody (nAb) escape, infectivity, fusion, and spike stability of these subvariants—LB.1, KP.2.3, KP.3, and KP.3.1.1. Our findings demonstrate that all of these subvariants are highly evasive of nAbs elicited by the bivalent mRNA vaccine, the XBB.1.5 monovalent mumps virus-based vaccine, or from infections during the BA.2.86/JN.1 wave. This reduction in nAb titers is primarily driven by a single serine deletion (DelS31) in the NTD of the spike, leading to a distinct antigenic profile compared to the parental JN.1 and other variants. We also found that the DelS31 mutation decreases pseudovirus infectivity in CaLu-3 cells, which correlates with impaired cell-cell fusion. Additionally, the spike protein of DelS31 variants appears more conformationally stable, as indicated by reduced S1 shedding both with and without stimulation by soluble ACE2 and increased resistance to elevated temperatures. Molecular modeling suggests that DelS31 enhances the NTD-receptor-binding domain (RBD) interaction, favoring the RBD down conformation and reducing accessibility to ACE2 and specific nAbs. Moreover, DelS31 introduces an N-linked glycan at N30, shielding the NTD from antibody recognition. These findings underscore the role of NTD mutations in immune evasion, spike stability, and viral infectivity, highlighting the need to consider DelS31-containing antigens in updated COVID-19 vaccines. IMPORTANCE: The emergence of novel severe acute respiratory syndrome coronavirus 2 variants continues to pose challenges for global public health, particularly in the context of immune evasion and viral stability. This study identifies a key N-terminal domain (NTD) mutation, DelS31, in JN.1-derived subvariants that enhances neutralizing antibody escape while reducing infectivity and cell-cell fusion. The DelS31 mutation stabilizes the spike protein conformation, limits S1 shedding, and increases thermal resistance, which possibly contribute to prolonged viral persistence. Structural analyses reveal that DelS31 enhances NTD-receptor-binding domain interactions by introducing glycan shielding, thus decreasing antibody and ACE2 accessibility. These findings emphasize the critical role of NTD mutations in shaping viral evolution and immune evasion, underscoring the urgent need for updated coronavirus disease 2019 vaccines that account for these adaptive changes.
- 14 May 2025
- Published by American Society for Microbiology in mBio
- Vol. 16 (5) , e0046425
Top Cited PapersOpen AccessNeutralization and spike stability of JN.1-derived LB.1, KP.2.3, KP.3, and KP.3.1.1 subvariants
During the summer of 2024, coronavirus disease 2019 (COVID-19) cases surged globally, driven by variants derived from JN.1 subvariants of severe acute respiratory syndrome coronavirus 2 that feature new mutations, particularly in the N-terminal domain (NTD) of the spike protein. In this study, we report on the neutralizing antibody (nAb) escape, infectivity, fusion, and spike stability of these subvariants—LB.1, KP.2.3, KP.3, and KP.3.1.1. Our findings demonstrate that all of these subvariants are highly evasive of nAbs elicited by the bivalent mRNA vaccine, the XBB.1.5 monovalent mumps virus-based vaccine, or from infections during the BA.2.86/JN.1 wave. This reduction in nAb titers is primarily driven by a single serine deletion (DelS31) in the NTD of the spike, leading to a distinct antigenic profile compared to the parental JN.1 and other variants. We also found that the DelS31 mutation decreases pseudovirus infectivity in CaLu-3 cells, which correlates with impaired cell-cell fusion. Additionally, the spike protein of DelS31 variants appears more conformationally stable, as indicated by reduced S1 shedding both with and without stimulation by soluble ACE2 and increased resistance to elevated temperatures. Molecular modeling suggests that DelS31 enhances the NTD-receptor-binding domain (RBD) interaction, favoring the RBD down conformation and reducing accessibility to ACE2 and specific nAbs. Moreover, DelS31 introduces an N-linked glycan at N30, shielding the NTD from antibody recognition. These findings underscore the role of NTD mutations in immune evasion, spike stability, and viral infectivity, highlighting the need to consider DelS31-containing antigens in updated COVID-19 vaccines. IMPORTANCE: The emergence of novel severe acute respiratory syndrome coronavirus 2 variants continues to pose challenges for global public health, particularly in the context of immune evasion and viral stability. This study identifies a key N-terminal domain (NTD) mutation, DelS31, in JN.1-derived subvariants that enhances neutralizing antibody escape while reducing infectivity and cell-cell fusion. The DelS31 mutation stabilizes the spike protein conformation, limits S1 shedding, and increases thermal resistance, which possibly contribute to prolonged viral persistence. Structural analyses reveal that DelS31 enhances NTD-receptor-binding domain interactions by introducing glycan shielding, thus decreasing antibody and ACE2 accessibility. These findings emphasize the critical role of NTD mutations in shaping viral evolution and immune evasion, underscoring the urgent need for updated coronavirus disease 2019 vaccines that account for these adaptive changes.